This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the US I am a US resident I am a patient outside the US
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Patient FAQ
Tips For Taking TASIGNA
TASIGNA Daily Planner
Select Times
12 PM & 12 AM
1 PM & 1 AM
2 PM & 2 AM
3 PM & 3 AM
4 PM & 4 AM
5 PM & 5 AM
6 PM & 6 AM
7 PM & 7 AM
8 PM & 8 AM
9 PM & 9 AM
10 PM & 10 AM
11 PM & 11 AM

References:
1. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.
2. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2012.


TASIGNA Interactive Game

To see how TASIGNA is an optimized BCR-ABL inhibitor that was designed to improve on imatinib, go to TASIGNA mechanism of action1

Learn how the favorable tolerability profile may help patients adhere to therapy2